[Use of biologically active supplement containing omega-3 polyunsaturated fatty acids in patients with type 2 diabetes mellitus].

35 patients with diabetes mellitus type 2 complicated with hyperlipidemia, coronary heart disease were treated during 8 months with poseidonol--polyunsaturated fatty acid family omega 3 (PUFA--omega 3). It was shown that hypercoagulation and hypofibrinolysis in these patients occurred. Treatment with poceidonol increased plasminogen activator activity and decreased coagulation and reduced atherogenic index.